BNP Paribas Arbitrage SA raised its holdings in CareDx, Inc (NASDAQ:CDNA) by 24.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,745 shares of the company’s stock after purchasing an additional 1,692 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in CareDx were worth $595,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Cowa LLC purchased a new stake in CareDx in the fourth quarter valued at $32,000. Capital Asset Advisory Services LLC purchased a new stake in CareDx in the fourth quarter valued at $32,000. IFP Advisors Inc boosted its holdings in CareDx by 16,600.0% in the first quarter. IFP Advisors Inc now owns 501 shares of the company’s stock valued at $34,000 after purchasing an additional 498 shares during the last quarter. Advisory Services Network LLC boosted its stake in shares of CareDx by 22.0% during the 4th quarter. Advisory Services Network LLC now owns 638 shares of the company’s stock worth $46,000 after acquiring an additional 115 shares in the last quarter. Finally, Orion Capital Management LLC purchased a new stake in shares of CareDx during the 4th quarter worth about $51,000.
Several equities research analysts have recently issued reports on the stock. HC Wainwright lowered shares of CareDx from a “buy” rating to a “neutral” rating in a research note on Friday, February 26th. Piper Sandler increased their target price on shares of CareDx from $93.00 to $100.00 and gave the stock an “overweight” rating in a research note on Thursday, May 6th. TheStreet raised shares of CareDx from a “d” rating to a “c-” rating in a research note on Friday, March 19th. Zacks Investment Research raised shares of CareDx from a “sell” rating to a “hold” rating in a research note on Tuesday, April 27th. Finally, Raymond James lowered their target price on shares of CareDx from $98.00 to $90.00 and set a “strong-buy” rating on the stock in a research note on Thursday, May 6th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. CareDx presently has a consensus rating of “Buy” and a consensus target price of $76.13.
CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, May 5th. The company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.13. The firm had revenue of $67.40 million for the quarter, compared to analyst estimates of $60.77 million. CareDx had a negative net margin of 6.14% and a negative return on equity of 4.25%. Equities research analysts expect that CareDx, Inc will post -0.33 EPS for the current fiscal year.
In other CareDx news, insider Peter Maag sold 26,500 shares of the stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $86.25, for a total value of $2,285,625.00. Following the completion of the sale, the insider now owns 393,977 shares in the company, valued at approximately $33,980,516.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CMO Sasha King sold 8,071 shares of the stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $90.01, for a total transaction of $726,470.71. Following the completion of the sale, the chief marketing officer now owns 50,567 shares of the company’s stock, valued at approximately $4,551,535.67. The disclosure for this sale can be found here. In the last quarter, insiders sold 161,329 shares of company stock valued at $12,135,976. 4.60% of the stock is owned by insiders.
CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection.
See Also: Why Invest in Dividend Kings
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.